In April 2025 C.E., New Mexico Governor Michelle Lujan Grisham signed Senate Bill 219 — the Medical Psilocybin Act — into law, making the state the third in the country to open a legal pathway for psilocybin therapy. Oregon and Colorado moved first, both through ballot initiatives. New Mexico did it differently: through the state legislature, with a Senate vote of 33 to 4 and a House vote of 56 to 8. That kind of bipartisan margin on a Schedule I substance is not a routine political event.
At a glance
- Psilocybin therapy: New Mexico’s Medical Psilocybin Act creates a regulated clinical framework for treating major treatment-resistant depression, PTSD, substance use disorders, and end-of-life distress in approved facilities under trained clinicians.
- Equity fund: The law allocates $630,000 specifically to subsidize treatment for low-income patients — believed to be the first government funding anywhere in the world dedicated to psychedelic therapy access for people without disposable income.
- Implementation timeline: The program is mandated to be operational by December 31, 2027 C.E., but state health officials announced in December 2025 C.E. they were targeting first patient access by end of 2026 C.E. — a full year ahead of schedule.
Why the legislative path changes things
Oregon’s Measure 109 passed in 2020 C.E. Colorado’s Proposition 122 passed in 2022 C.E. Both were citizen ballot initiatives, which means both require another public vote to amend — even for technical corrections. Implementation delays and legal challenges have followed in both states.
Because New Mexico’s program was passed through the legislature, lawmakers can revise SB 219 directly as clinical evidence develops and real-world experience accumulates. No referendum required. That flexibility could matter enormously as the science moves and the program scales.
Affordability has been the most visible failure of Oregon’s rollout. A single psilocybin therapy session in Oregon costs $1,500 to $3,500. Most patients with treatment-resistant depression or PTSD cannot cover that out of pocket, and no state mandates insurance coverage. New Mexico’s equity fund acknowledges that problem from day one — a therapy accessible only to people who can afford it is not a public health program.
What the program actually looks like
The framework is deliberately clinical. Every session must take place in a New Mexico Department of Health-approved facility. Clinicians must complete a DOH-established training program. Patients must carry a qualifying diagnosis: treatment-resistant depression, PTSD, a substance use disorder, or a terminal illness requiring end-of-life support.
Sessions follow a three-part structure — preparation, guided psilocybin therapy, and integration. Only natural psilocybin mushrooms are permitted; synthetic psilocybin is not authorized under the Act. Licensed providers are protected from criminal charges but remain subject to civil malpractice liability, and protections apply only to activities explicitly authorized under the program.
A nine-member Medical Psilocybin Advisory Board will set guidelines, training standards, and future policy. Its required composition is worth noting: at least one member enrolled in a New Mexico Indian nation, tribe, or pueblo; at least one behavioral health equity advocate; and at least one U.S. armed forces veteran. The University of New Mexico — historically a leading institution in psychedelics research — stands to benefit directly from a separate research fund also established under the law.
The limitation the law doesn’t hide
The Medical Psilocybin Act is explicit about what it does not do. Possession, use, cultivation, or sale of psilocybin mushrooms outside the medical program remains illegal under both New Mexico state law and federal law. The bill’s text states directly that it “does not propose broad decriminalization of psilocybin” and that legal protections are “narrowly tailored.”
That gap is real. Someone who uses psilocybin outside the approved clinical system — even for personal therapeutic purposes — still faces criminal exposure. The law creates a medical program, not a general civil liberty, and that distinction matters for the many people who will never qualify or never gain access.
Still, Senator Jeff Steinborn, the bill’s co-sponsor, called the first Advisory Board meeting in December 2025 C.E. “a historic day not just for the state, but really even for the whole country and the whole world.” That may be measured language for once.
Part of a faster-moving picture
Psilocybin therapy is one thread in a broader shift in mental health science. Researchers are finding approaches to conditions long considered untreatable — a pattern visible in falling cancer death rates in the U.K. and in other health milestones accumulating across the decade. Each development shifts what feels politically possible.
New Mexico is a state with significant rural populations, Indigenous communities, and veterans — groups that carry disproportionate burdens of PTSD and treatment-resistant depression and have historically been underserved by conventional mental health systems. Whether the equity fund and the board’s composition translate into real access for those communities remains to be seen. The evidence base for psilocybin in PTSD treatment is still developing, and clinical infrastructure takes time to build.
But a legislature voting 56 to 8 to fund psychedelic-assisted therapy — and explicitly allocating money so low-income patients can use it — is a different kind of signal than a ballot measure scraping past 51 percent. It suggests the political center of gravity has moved, and it moved through elected representatives, not around them. That’s something that can be built on.
For readers tracking milestones in representation and equity across other fields, the story of Marie-Louise Eta becoming the first female head coach in men’s top-flight European football offers a similar note — barriers fall when institutions make deliberate structural choices, not just symbolic gestures.
Read more
For more on this story, see: DoubleBlind Magazine
For more from Good News for Humankind, see:
- U.K. cancer death rates are at their lowest level on record
- Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
- The Good News for Humankind archive on health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana creates its first marine protected area to rescue depleted fish stocks
Ghana has declared its first marine protected area near Cape Three Points on the Gulf of Guinea, marking a historic step to reverse decades of overfishing. The protected zone aims to restore fish populations that have collapsed under pressure from industrial trawling and illegal fishing. The decision supports 2.7 million Ghanaians whose livelihoods depend on healthy coastal fisheries and aligns Ghana with the global goal of protecting 30 percent of the world’s oceans by 2030.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
For the first time, researchers have evidence that removing amyloid plaques from the brain before symptoms appear can cut Alzheimer’s risk by roughly half. A clinical trial published in The Lancet Neurology, led by Washington University School of Medicine in St. Louis, found that long-term treatment with the antibody drug gantenerumab significantly delayed dementia onset in people with a rare genetic form of the disease. The findings provide the clearest signal yet that intervening years before symptoms emerge can change the course of Alzheimer’s disease.
